2024
Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients
Ranjan S, Leung D, Ghiaseddin A, Taylor J, Lobbous M, Dhawan A, Budhu J, Coffee E, Melnick K, Chowdhary S, Lu‐Emerson C, Kurz S, Burke J, Lam K, Patel M, Dunbar E, Mohile N, Peters K. Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients. Cancer 2024, 130: 1577-1589. PMID: 38288941, DOI: 10.1002/cncr.35220.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsLow-molecular-weight heparinVenous thromboembolismIntracranial hemorrhageBrain tumorsEfficacy of direct oral anticoagulantsMetastatic brain tumor patientsRisk of intracranial hemorrhageTreatment of venous thromboembolismManagement of venous thromboembolismMetastatic brain tumorsOral anticoagulant useTreat venous thromboembolismOff-label useBrain tumor patientsBrain metastasesOral anticoagulantsAnticoagulant useTumor patientsClinical trialsPatientsClinical guidanceThromboembolismGlioblastomaHeparin
2022
Low Molecular Weight Heparin, Unfractionated Heparin and Neuraxial Anaesthesia
Combs D, Leffert L. Low Molecular Weight Heparin, Unfractionated Heparin and Neuraxial Anaesthesia. 2022, 329-335. DOI: 10.1007/978-3-030-72487-0_49.Peer-Reviewed Original ResearchThe relationship between INTEM/HEPTEM coagulation time ratio and heparin plasma concentration in obstetric patients: an exploratory in vitro investigation
Katz D, Leffert L, Getrajdman C, Sison M, Shin DW, Lin HM, Butwick A. The relationship between INTEM/HEPTEM coagulation time ratio and heparin plasma concentration in obstetric patients: an exploratory in vitro investigation. Journal Canadien D'anesthésie 2022, 69: 597-604. PMID: 35102496, DOI: 10.1007/s12630-022-02193-5.Peer-Reviewed Original ResearchConceptsObstetric patientsUnfractionated heparinConcentration of heparinHeparin activityHeparin concentrationPartial thromboplastin time (aPTT) testingCT ratioCare coagulation testsHeparin plasma concentrationsResultsSeventy-seven patientsPartial thromboplastin timeUncomplicated pregnanciesThird trimesterNeuraxial anestheticPlasma concentrationsCoagulation testsThromboplastin timeBlood samplesPatientsHeparinAPTTHematocrit rangeVitro investigationBloodTime ratio
2020
The Application of ROTEM in a Parturient With Antiphospholipid Syndrome in the Setting of Anticoagulation for Cesarean Delivery: A Case Report.
Fiol AG, Fardelmann KL, McGuire PJ, Merriam AA, Miller A, Alian A. The Application of ROTEM in a Parturient With Antiphospholipid Syndrome in the Setting of Anticoagulation for Cesarean Delivery: A Case Report. A&A Practice 2020, 14: e01182. PMID: 32224689, DOI: 10.1213/xaa.0000000000001182.Peer-Reviewed Case Reports and Technical NotesConceptsAntiphospholipid syndromeHeparin neutralizationDiagnosis of hemolysisElevated liver enzymesSetting of anticoagulationFresh frozen plasmaPartial thromboplastin timeCesarean deliveryLow plateletsTransfusion managementCase reportFrozen plasmaLiver enzymesThromboplastin timeParturientsSyndromeIntrinsic pathwayAnticoagulationROTEMDiagnosisNeutralizationHeparin
2019
Comparing the Ability of Unfractionated Heparin, Enoxaparin, and Nadroparin to Augment C1 Esterase Inhibitor Activity in Sera of Patients with Hereditary Angioedema
Chan E, Dennis J, Woroch E, Hellbusch B, Shaun B, Schmidt E, Aerts S, Bates M, Fugit R, Nieto-Martinez S, Majluf-Cruz A, Giclas P, Frazer-Abel A, Zhou Y. Comparing the Ability of Unfractionated Heparin, Enoxaparin, and Nadroparin to Augment C1 Esterase Inhibitor Activity in Sera of Patients with Hereditary Angioedema. 2019, a2975-a2975. DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2975.Peer-Reviewed Original Research
2018
Neuraxial Anesthesia in Obstetric Patients Receiving Thromboprophylaxis With Unfractionated or Low–Molecular-Weight Heparin
Leffert L, Dubois H, Butwick A, Carvalho B, Houle T, Landau R. Neuraxial Anesthesia in Obstetric Patients Receiving Thromboprophylaxis With Unfractionated or Low–Molecular-Weight Heparin. Obstetric Anesthesia Digest 2018, 38: 3-4. DOI: 10.1097/01.aoa.0000529964.63597.d5.Peer-Reviewed Original ResearchSpinal epidural hematomaObstetric patientsNeuraxial anesthesiaWeight heparinVenous thromboembolismCesarean deliveryEpidural hematomaPregnant womenNeuraxial blockadeNational guidelinesPatientsThromboprophylaxisHeparinAnesthesiaSafe useWomenLow-MolecularThromboembolismHematomaBlockadeReview reportsPresent review reports
2017
Successful anticoagulation therapy for a giant left atrial thrombus following mitral valve repair
Mathew EN, Pang PYK, Mori M, Chua YL, Sin YK. Successful anticoagulation therapy for a giant left atrial thrombus following mitral valve repair. Journal Of Thoracic Disease 2017, 9: e640-e643. PMID: 28840033, PMCID: PMC5542978, DOI: 10.21037/jtd.2017.06.84.Peer-Reviewed Original ResearchMitral valve repairAtrial thrombusAtrial fibrillationValve repairSerial brain imagingSubtherapeutic anticoagulationSurgical thrombectomyAnticoagulation therapyConcomitant proceduresNeurological deficitsTherapeutic warfarinWeight heparinComplete resolutionThrombusBrain imagingEchocardiographyWarfarinRepairAnticoagulationThrombectomyInfarctsPatientsFibrillationTherapyHeparin
2015
Polysulfated Trehalose as a Novel Anticoagulant Agent with Dual Mode of Action
Rashid Q, Abid M, Gupta N, Tyagi T, Ashraf M, Jairajpuri M. Polysulfated Trehalose as a Novel Anticoagulant Agent with Dual Mode of Action. BioMed Research International 2015, 2015: 630482. PMID: 25866798, PMCID: PMC4381846, DOI: 10.1155/2015/630482.Peer-Reviewed Original ResearchConceptsFavorable safety profileNovel anticoagulant agentsForm of heparinAnticoagulant administrationSafety profileAntithrombotic agentsAnticoagulant agentsAnticoagulant factorsHemostatic balanceAntithrombotic potentialLow doseAntiplatelet mechanismFibrinolytic systemPlatelet aggregationThrombotic ratsFirst lineHeparinCoagulation timeRatsBlood plasmaNovel compoundsThromboembolismComplicationsAnticoagulantsTherapyHeparin is an activating ligand of the orphan receptor tyrosine kinase ALK
Murray PB, Lax I, Reshetnyak A, Ligon GF, Lillquist JS, Natoli EJ, Shi X, Folta-Stogniew E, Gunel M, Alvarado D, Schlessinger J. Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK. Science Signaling 2015, 8: ra6. PMID: 25605972, DOI: 10.1126/scisignal.2005916.Peer-Reviewed Original ResearchConceptsAnaplastic lymphoma kinaseReceptor tyrosine kinasesActivation of RTKsCultured neuroblastoma cellsReceptor tyrosine kinase anaplastic lymphoma kinaseActivation of ALKStroma contributesLung adenocarcinomaLymphoma kinaseNervous systemExtracellular domainDrug resistanceNeuroblastoma cellsAberrant activationALK activityHeparinCancerPotential mechanismsGenetic amplificationActivationTyrosine kinaseAdenocarcinomaNeuroblastomaTherapyProgression262: Heparin stimulates placental release and increases circulating levels of amyloid-like aggregates in women with prophylactic anticoagulation
Millen K, Buhimschi C, Zhao G, Tabbah S, Thung S, Paidas M, Funai E, Buhimschi I. 262: Heparin stimulates placental release and increases circulating levels of amyloid-like aggregates in women with prophylactic anticoagulation. American Journal Of Obstetrics And Gynecology 2015, 212: s144. DOI: 10.1016/j.ajog.2014.10.308.Peer-Reviewed Original Research
2014
BIVALIRUDIN VERSUS HEPARIN WITH OR WITHOUT GLYCOPROTEIN IIB/IIIA INHIBITORS IN STEMI PATIENTS UNDERGOING PRIMARY PCI: A POOLED ANALYSIS OF PATIENT-LEVEL DATA FROM THE HORIZONS-AMI AND EUROMAX TRIALS
Steg P, Mehran R, Goldstein P, Witzenbichler B, Hof A, Guagliumi G, Hamm C, Genereux P, Clemmensen P, Parise H, Pocock S, Gersh B, Bernstein D, Deliargyris E, Stone G, Bichat H. BIVALIRUDIN VERSUS HEPARIN WITH OR WITHOUT GLYCOPROTEIN IIB/IIIA INHIBITORS IN STEMI PATIENTS UNDERGOING PRIMARY PCI: A POOLED ANALYSIS OF PATIENT-LEVEL DATA FROM THE HORIZONS-AMI AND EUROMAX TRIALS. Journal Of The American College Of Cardiology 2014, 63: a34. DOI: 10.1016/s0735-1097(14)60034-6.Peer-Reviewed Original Research
2010
Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro
Adam A, Montpas N, Keire D, Désormeaux A, Brown NJ, Marceau F, Westenberger B. Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro. Biomaterials 2010, 31: 5741-5748. PMID: 20427081, PMCID: PMC2896062, DOI: 10.1016/j.biomaterials.2010.03.074.Peer-Reviewed Original ResearchConceptsContact system activationAnaphylactoid reactionsOversulfated chondroitin sulfateSystem activationSevere anaphylactoid reactionPlasma contact systemHuman plasmaInflammatory peptidesChondroitin sulfateEnzyme inhibitorsBK releaseDrug AdministrationBradykininHeparinSignificant correlationDefinitive evidenceDextran sulfatePlasma dilutionActivationConclusionPatientsPathophysiologyKininsAdministrationPlasma
2009
Structural Characterization of the E2 Domain of APL-1, a Caenorhabditis elegans Homolog of Human Amyloid Precursor Protein, and Its Heparin Binding Site*
Hoopes JT, Liu X, Xu X, Demeler B, Folta-Stogniew E, Li C, Ha Y. Structural Characterization of the E2 Domain of APL-1, a Caenorhabditis elegans Homolog of Human Amyloid Precursor Protein, and Its Heparin Binding Site*. Journal Of Biological Chemistry 2009, 285: 2165-2173. PMID: 19906646, PMCID: PMC2804372, DOI: 10.1074/jbc.m109.018432.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceAmyloid beta-Protein PrecursorAnimalsBinding SitesCaenorhabditis elegansCaenorhabditis elegans ProteinsCrystallography, X-RayHeparinHumansHydrogen-Ion ConcentrationMembrane ProteinsModels, MolecularMolecular Sequence DataMutagenesis, Site-DirectedMutationProtein StabilityProtein Structure, TertiarySequence Homology, Amino AcidSolutionsSucrose
2008
388: Heparin stimulates placental release and increases circulating levels of sFlt-1 in women with prophylactic anticoagulation
Rosenberg V, Buhimschi I, Paidas M, Zhao G, Baumbusch M, Dulay A, Lockwood C, Buhimschi C. 388: Heparin stimulates placental release and increases circulating levels of sFlt-1 in women with prophylactic anticoagulation. American Journal Of Obstetrics And Gynecology 2008, 199: s118. DOI: 10.1016/j.ajog.2008.09.417.Peer-Reviewed Original Research
2006
Cardiac surgery in a patient with heparin-induced thrombocytopenia--cautions with use of the direct thrombin inhibitor, argatroban.
Kurup V, Transue S, Wu Y, Rinder HM, Barash P, Dewar M. Cardiac surgery in a patient with heparin-induced thrombocytopenia--cautions with use of the direct thrombin inhibitor, argatroban. Connecticut Medicine 2006, 70: 245-50. PMID: 16768071.Peer-Reviewed Original ResearchConceptsDirect thrombin inhibitorCardiopulmonary bypassCardiac surgeryThrombin inhibitorsCoronary bypass graft surgeryBypass graft surgeryAortic valve replacementNumber of patientsPresent case reportGraft surgeryValve replacementCase reportPharmacologic basisBlood productsHeparin substitutePatientsSurgeryArgatrobanPrevious exposurePertinent reportsHeparinThrombocytopeniaSubstantial numberInhibitorsReport
2004
Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates1
Koyama I, Kawai T, Andrews D, Boskovic S, Nadazdin O, Wee S, Sogawa H, Wu D, Smith R, Colvin R, Sachs D, Cosimi A. Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates1. Transplantation 2004, 77: 460-462. PMID: 14966427, DOI: 10.1097/01.tp.0000110291.29370.c0.Peer-Reviewed Original ResearchConceptsIncidence of thrombosisRecipients treated with anti-CD154 mAbAnti-CD154 mAb treatmentAnti-CD154 mAbMonoclonal antibody treatmentMAb treatmentAnticoagulant prophylaxisKetorolac administrationConsecutive recipientsPerioperative heparinThromboembolic complicationsAntibody treatmentNo thrombosisPlatelet activationKetorolacProphylaxisComplicationsThrombosisNonhuman primatesIncidenceTreatmentRecipientsHeparinThrombophiliaThromboembolism
2003
Relation between the degree of procedural anticoagulation and complications after coronary stent implantation
Ashby DT, Dangas G, Aymong EA, Farkouh ME, Mehran R, Lansky AJ, Moses JW, Leon MB, Stone GW. Relation between the degree of procedural anticoagulation and complications after coronary stent implantation. The American Journal Of Cardiology 2003, 92: 319-322. PMID: 12888144, DOI: 10.1016/s0002-9149(03)00637-4.Peer-Reviewed Original Research
2002
The HEP@NET study: an internet-based registry examining the efficacy of heparin coating in patients undergoing coronary stent implantation
Mehran R, Lotan C, Kranjec I, Holmer E, Haase K, Camenzind E, Zelizko M, Maillard L, Seabra-Gomes R, Vandormael M, Lansky A, Dangas G, Stone G, Ashby D, Leon M. The HEP@NET study: an internet-based registry examining the efficacy of heparin coating in patients undergoing coronary stent implantation. Journal Of The American College Of Cardiology 2002, 39: 75. DOI: 10.1016/s0735-1097(02)80322-9.Peer-Reviewed Original Research
1999
#432 Danaparoid (orgaran) anti-coagulation of pediatric patients with heparin-induced thrombocytopenia (HIT)
Weigel B, Lasky A, Krishnamurti L, Perentesis J, Neglia J, Foker J, Key N, Edson R, Steiner M. #432 Danaparoid (orgaran) anti-coagulation of pediatric patients with heparin-induced thrombocytopenia (HIT). Journal Of Pediatric Hematology/Oncology 1999, 21: 457. DOI: 10.1097/00043426-199909000-00035.Peer-Reviewed Original Research
1998
Heparin dosing in patients undergoing coronary intervention
Popma J, Prpic R, Lansky A, Piana R. Heparin dosing in patients undergoing coronary intervention. The American Journal Of Cardiology 1998, 82: 19p-24p. PMID: 9809888, DOI: 10.1016/s0002-9149(98)00759-0.Peer-Reviewed Original ResearchConceptsIIb/IIIa inhibitorsCoronary interventionHeparin therapyHemochron devicePlatelet glycoprotein IIb/IIIa inhibitorsGlycoprotein IIb/IIIa inhibitorsGP IIb/IIIa inhibitorsUncomplicated coronary interventionsWeight-adjusted heparinAntithrombotic regimenHemoTec deviceHeparin bolusHeparin dosingSufficient heparinHeparin administrationConventional heparinUnfractionated heparinSignificant thrombocytopeniaPatientsACT levelsHeparinLonger durationTarget ACTInterventionAnticoagulation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply